QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
NASDAQ:CRTX

Cortexyme - CRTX Stock Forecast, Price & News

$2.31
+0.17 (+7.94%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.11
$2.33
50-Day Range
$1.84
$3.28
52-Week Range
$1.78
$40.66
Volume
307,797 shs
Average Volume
620,672 shs
Market Capitalization
$69.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50

Cortexyme MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
484.4% Upside
$13.50 Price Target
Short Interest
Bearish
16.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$30,888 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.86) to ($2.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

682nd out of 1,112 stocks

Biological Products, Except Diagnostic Industry

105th out of 175 stocks

CRTX stock logo

About Cortexyme (NASDAQ:CRTX) Stock

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Cortexyme Stock Up 7.9 %

Shares of NASDAQ:CRTX opened at $2.31 on Thursday. Cortexyme has a twelve month low of $1.78 and a twelve month high of $40.66. The firm has a market cap of $69.65 million, a PE ratio of -0.78 and a beta of 1.23. The business has a fifty day simple moving average of $2.37 and a two-hundred day simple moving average of $3.94.

Cortexyme (NASDAQ:CRTX - Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.08). On average, research analysts expect that Cortexyme will post -2.86 earnings per share for the current year.

Insider Buying and Selling at Cortexyme

In other news, insider Caryn Gordon Mcdowell sold 10,800 shares of the company's stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $2.86, for a total value of $30,888.00. Following the completion of the sale, the insider now owns 122,500 shares of the company's stock, valued at approximately $350,350. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 27.90% of the company's stock.

Receive CRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

CRTX Stock News Headlines

Cortexyme Announces Agreement to Acquire Novosteo
See More Headlines
Receive CRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

CRTX Company Calendar

Last Earnings
8/09/2021
Today
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Health Care Technology
Sector
Medical
Current Symbol
NASDAQ:CRTX
CUSIP
21924P10
Fax
N/A
Employees
55
Year Founded
2012

Price Target and Rating

Average Stock Price Forecast
$13.50
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+484.4%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-89,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.97 per share

Miscellaneous

Free Float
21,739,000
Market Cap
$69.65 million
Optionable
Not Optionable
Beta
1.23

Social Links















CRTX Stock - Frequently Asked Questions

Should I buy or sell Cortexyme stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRTX, but not buy additional shares or sell existing shares.
View CRTX analyst ratings
or view top-rated stocks.

What is Cortexyme's stock price forecast for 2022?

6 brokerages have issued 12-month target prices for Cortexyme's shares. Their CRTX share price forecasts range from $12.00 to $15.00. On average, they predict the company's share price to reach $13.50 in the next twelve months. This suggests a possible upside of 484.4% from the stock's current price.
View analysts price targets for CRTX
or view top-rated stocks among Wall Street analysts.

How have CRTX shares performed in 2022?

Cortexyme's stock was trading at $12.62 at the beginning of 2022. Since then, CRTX shares have decreased by 81.7% and is now trading at $2.31.
View the best growth stocks for 2022 here
.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) issued its quarterly earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.05.

What other stocks do shareholders of Cortexyme own?

When did Cortexyme IPO?

(CRTX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Who are Cortexyme's major shareholders?

Cortexyme's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (1.88%) and Walleye Capital LLC (0.25%). Insiders that own company stock include Caryn Gordon Mcdowell, Casey Lynch, Christopher P Lowe, David Lamond, Epiq Capital Group, Llc, Leslie Holsinger, Margaret Mcloughlin, Michael J Detke and Stephen S Dominy.
View institutional ownership trends
.

How do I buy shares of Cortexyme?

Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $2.31.

How much money does Cortexyme make?

Cortexyme (NASDAQ:CRTX) has a market capitalization of $69.65 million. The biopharmaceutical company earns $-89,940,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis.

When was Cortexyme founded?

Cortexyme was founded in 2012.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cortexyme.com. The biopharmaceutical company can be reached via phone at (650) 910-5717 or via email at ir@cortexyme.com.

This page (NASDAQ:CRTX) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.